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Summary Surgical specimens from 15 medulloblastoma patients were used to establish early passage cultures.
In vitro sensitivity to a battery of cytotoxic agents, including some in current medulloblastoma treatment
protocols, was measured. Drug sensitivity was assessed at clinically relevant drug concentrations using the
3H-thymidine uptake method. Tumours were predicted to be sensitive if >37% were killed by exposure to
drugs at clinically achievable levels. A poor response to vincristine (Vcr), cis-platin (CDDP), hydroxyurea
(HU) or diaziquone (AZQ) (no responders), and cytosine arabinoside (AraC) (1/12), was seen.
Nine of ten tumours tested were sensitive to mafosfamide (Mfs); seven out of 12 were sensitive to
carmustine (BCNU), 12 of 13 to teniposide (VM-26) and seven of 13 to etoposide (VP16-213). VM-26 was the
best of the agents tested with most tumours responding to very low concentrations ofdrug, suggesting that the
role of epipodophyllotoxins in treatment of brain tumours be further investigated.
Despite the marked sensitivity of the medulloblastomas to the epipodophyllotoxins, three early passage
cultures were much more resistant to these drugs than the average for the group. The basis of this resistance
was investigated. Deficient cellular uptake of drug was excluded as a cause of resistance. One resistant early
passage culture displayed low cellular activity of topoisomerase II and decreased levels of drug induced
enzyme-DNA strand break activity. This was not the case for the other resistant early passage cultures: the
basis of resistance in these cells does not appear to be due to any previously reported mechanism.
Medulloblastoma is an important paediatric brain tumour
because of its high incidence and malignant behaviour. The
overall disease free survival at 5 years, in patients receiving
surgery and craniospinal axis radiotherapy, is approximately
50%. This is considered to be the upper limit ofcurability by
these treatment modalities. Chemotherapy has been shown to
be advantageous in selected patient groups either as adjuvant
therapy or as treatment of recurrent disease. The value of
chemotherapy in the treatment of medulloblastoma will be
dependent on the availability and identification of drugs
active against this tumour. At present, protocols for chemo-
therapy usually include the lipophilic compounds carmustine
(BCNU) or lomustine and procarbazine. Vincristine (Vcr),
whilst poorly absorbed by cerebrospinal fluid and brain, is
also commonly used (Bloom, 1986; Workman, 1986).
Currently '8 in 1F therapy is being evaluated (Pendergrass et
al., 1987).
Cytotoxicity has been assessed by clonal assays in agar or
on plastic, incorporation of 3H-thymidine into DNA, uptake
of vital dyes and other methods with much the same results.
Predictions of resistance are close to 100% correct; prediction
of sensitivity, whilst less reliable, still has a success rate of
around 70% (Salmon et al., 1980; Moon et al., 1981; Rosen-
bloom et al., 1983; Bogdahn, 1983; Kornblith et al., 1981;
Kimmel et al., 1987). We have examined drug sensitivity in
human medulloblastoma by using 14 early passage cultures.
Our study provides data on the degree of heterogeneity of
response between medulloblastomas obtained from a number
of patients. Furthermore, the cells were from early passage
cultures, and hence should give a better indication of chemo-
sensitivity of the tumours in vivo. The epipodophyllotoxins
teniposide (VM-26) and etoposide (VP16-213) were identified
as potentially useful agents in this disease. We investigated
the basis of primary clinical resistance to these drugs by
quantitating intracellular steady-state drug concentrations,
drug-induced protein-linked DNA strand breaks, and topo-
isomerase II expression and activity.
Materials and methods
Establishment ofcell cultures
All studies were made on material collected at procedures
performed for clinical reasons and remaining after sufficient
tissue has been taken for clinical laboratory study. The histo-
logical diagnosis was confirmed by an independent neuro-
pathologist (Professor B.W. Scheithauer). Over a period of 2
years, 16 medulloblastoma specimens were received from a
total of 15 patients. The age of the patients ranged from 3 to
11 years (median 5.5 years) with a male to female ratio of
2:1. Most of the samples were from primary tumours how-
ever both a primary tumour (MD 6) and a metastasis remov-
ed at the same time (MD 6M) were obtained from one
patient. A recurrent fourth ventricle tumour (MD 5) was
removed 3 years after a patient had completed a full course
ofcraniospinal irradiation and post irradiation chemotherapy
and in another patient a frontal metastasis (MD 14) was
removed 15 months following extirpation of the primary
lesion and a full course of craniospinal irradiation.
Tumours samples were dissociated and cloned in agar as
described by Ablett et al. (1984). Primary cultures, were
established in tissue culture flasks from dissociated tumour
cells in RPMI 1640 with 10% FCS, were incubated at 37°C
in an environment of 5% 02, 5% C02, 90% N2 and 100%
humidity. When the monolayers were almost confluent, the
cultures were passed. Cultures were characterised around
passage No. 4 and against around passage No. 10. Experi-
ments were not performed on cells after 12 passages. They
were routinely checked for mycoplasma.
Characterisation ofearly passage cultures
The early passage cultures were characterised by immuno-
histochemical methods for neuron specific enolase (NSE)
(Dako PAP kit, Dako Corp., Santa Barbara, USA) and by
a panel of monoclonal antibodies (UJ13A and A2B5 which
bind to normal and neoplastic neuroectodermal tissue,
UJ181.4 which shows specificity to oncofoetal antigen
expressed by foetal brain and neuroblastic tumours and
UJ127.11 which recognises antigens of normal neuroectoder-
mal tissue, neuronal tumours and schwannomas) all of which
were kindly provided by Dr J.T. Kemshead (Brain Tumour
Research Laboratory, Frenchay Hospital, Bristol, England)
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(Coakham et al., 1984). As frozen material was not available,
immunohistochemical staining was not performed on the
surgical specimen. Cytogenetic analysis was performed on
early passage cultures as described by Sandburg (1980).
Metaphases were G- banded (G- bands with Trypsin and
Giemsa). At least five metaphases were examined per culture.
DNA flow cytometry was performed as described by Pemble
et al. (1987). Normal HeLa cells were used as control.
Drug testing protocol
A reduction in survival, at clinically achievable drug levels, to
37% was adopted for classifying tumours into sensitive and
resistant groups (Salmon et al., 1980; Moon et al., 1981;
Lihou & Smith, 1983 & 1985; Kornblith et al., 1981; Rosen-
bloom et al., 1983; Kimmel et al., 1987). The pharmaco-
kinetic parameter C x T (concentration time.product) (Mellett,
1974; Alberts et al., 1980) was used as the measure of
clinically achievable drug exposure. The C x T achieved in
patients receiving standard drug doses was obtained from, or
calculated from published data (Tables I, II). The in vitro
C x T required to reduce survival to 37% was calculated
simply by multiplying the D37, the drug concentration requir-
ed to reduce survival to 37% of control values, by the
number of hours of incubation i.e. 24 h (Tables I, II). This
was compared with the C x T achievable in patients (Tables
I, II): tumours were classified as sensitive if the former figure
was less than the latter.
The medulloblastoma cells were exposed for 4 h to drugs
generally regarded as cycle specific, but not phase-specific
(diaziquone (AZQ) cis-platin (CDDP), mafosfamide (Mfs),
adriamycin (Adr)) (Chabner & Collins, 1990). Cells were
exposed to BCNU (cycle-specific drug) for 24h, since the
drug has a short half-life (t1/2). At 37C, the t1/2 of BCNU in
vitro is 12 min (Russo et al., 1987), hence the drug concentra-
tion is close to 0 after about 2 h. It was calculated that a 24 h
incubation with 10 .lM BCNU resulted in an in vitro C x T of
2.9 LM.h. The alkylating activity of Mfs in vitro was calcu-
lated assuming rapid hydrolysis to 4-OH cyclophosphamide
(Niemeyer et al., 1984) and an alkylating activity half-life for
4-OH cyclophosphamide in vitro of 3 h (Draeger et al., 1976).
A 4 h incubation with 20 t4M Mfs results in a C x T for
alkylating equivalents of 52 t4M.h. Early passage cultures
Table I Sensitivity of medulloblastomas to phase specific agents
D37 (IAM)a
Culture Vcr AraC HU VM-26 VP16-213
MD 3 0.158 1.23 32,460 0.66 4.36
MD 4 0.257 0.17 22,100 0.92 2.00
MD 5 0.131 2.79 16,800 15.17 43.92
MD 6 0.144 3.77 15,440 0.67 25.37
MD 7 0.277 - 2,950 49.30 37.21
MD 9 0.377 7.36 5,800 0.75 3.81
MD 10 0.123 1.29 - 1.05 3.51
MD 11 0.205 1.29 3,200 11.60 30.46
MD 12 0.012 0.42 570 0.03 0.19
MD 13 0.096 4.66 26,560 0.95 4.42
MD 14 0.060 2.40 3,010 0.20 1.44
MD 15 0.053 2.58 50,330 0.20 0.41
MD 17 0.469 0.83 2,960 0.16 0.58
Sensitiveb 0/13 1/12 0/11 12/13 7/13
Dose response curves were repeated 3-9 times for each culture and
each agent. The mean value of response at each dose was calculated
together with the standard error (s.e.m.) which ranged from 5-15% of
the mean value. aD37 values were calculated from these curves by linear
regression analysis. 'Tumour cell lines were classified as sensitive to an
agent if D37 x duration of exposure was less than the clinically
achievable C x T in patients. In vivo pharmacokinetic parameters of
dose (mg m-2), C x T (JM.h) and peak plasma concentration (P1M) are
as follows: vincristine (Vcr)
- 1.5, 0.11 and 0.70 (Owellan et al., 1977);
cytosine arabinoside (AraC)- 300, 17.7, 22.6 (Ho & Frei, 1971);
hydroxyurea (HU) - 3000 p.o, 1703, 191 (Davidson & Winter, 1963);
teniposide (VM-26)
- 165, 370, 51.3 (Allen & Creavan, 1975) and
etoposide (VP16-213) 100, 103, 17.7 (Allen & Creaven, 1975). Not
done.
Table II Sensitivity of medulloblastomas to BCNU, Mfs, CDDP,
AZQ
D37 (11M)a
Culture BCNU Mfs CDDP AZQ
MD3 7.64 42.49 7.71 288
MD4 8.80 14.56 8.80 294
MD5 - 52.92 4.54 420
MD6 31.41 51.66 5.30 66
MD7 30.25 83.41 9.14 350
MD 9 2.64 29.40 3.20 -
MD 10 8.68 15.85 7.88 63
MDll 23.48 47.74 7.44 166
MD12 7.24 3.60 1.80 -
MD13 9.75 - 6.16 26
MD 14 9.36 - - -
MD 15 12.07 - 5.31 -
MD 17 33.00 - 16.93 -
Sensitiveb 7/12 9/10 0/12 0/8
a137wascalculatedasoutlinedforTableI.TheD37valuesgivenabove
were calculated from the initial drug concentration in the incubation.
Thesefigureshavenotbeenadjustedto takeintoaccountactivitydecay.
bTumours were classified as sensitive or resistant as described forTable
I. TheD37 x durationofexposurevalueswerecalculatedassumingat/2
for BCNU of 12 min and rapid hydrolysis of mafosfamide (Mfs) to
4-OH-cyclophosphamide and t1/2 for alkylating activity for this com-
pound of 3 h. In vivo pharmacokinetic parameters of dose (mg m-2),
C x T (M.h) and peak plasma concentration (gM) are as follows:
carmustine (BCNU) -60, 3.1, 6.0(Levinetal., 1978); Mfs, derived data
from cyclophosphamide pharmacokinetic dose and C x T values -
1,200, 1,280 (Grochow & Colvin, 1979). Expressed as alkylating
equivalents C x T and peak plasma concentration values are 139 and
27; cis-platin (CDDP) -90, 5.9, 7.5 (Patton etal., 1978) and diaziquone
(AZQ) - 9, 4.07 and 0.37 (Lu et al., 1983). - Not done.
were exposed to the phase-specific agents i.e. cytosine ara-
binoside (AraC), hydroxyurea (HU), VM-26 and VP16-213
for 24 h, since the cells grew slowly. The doubling time up to
the 10th passage was around 3 days for all early passage
cultures except MD 12 (1.2 days).
Cell survival
Cell survival was determined by 3H-thymidine incorporation.
Early passage cultures were seeded in 0.1 ml of medium, in
96-well microtitre plates 24 h before treatment with drug (six
replicates for each drug concentration) at a cell concentration
of 4 x I04ml-'. The cells were exposed to drugs whilst
attached to the bottom of wells in microtitre plates. Control
untreated cells were examined daily until almost confluent.
Five to 7 days after treatment was initiated, the medium was
replaced with medium containing [3H-methyl]-thymidine (5 ytCi
ml-', 40Ci mmol -; RadioChemical Centre, Amersham, UK).
After 24 h at 37°C, the cells were washed with Dulbecco's
solution, detached with 1.25 mgml' pancreatin (Sigma, St
Louis, USA), 0.16M NaCl, 6mM Na2HPO4, 2.7mM KCI,
1.5 mM KH2PO4 hand 6.0mM EDTA, pH 7.2, filtered onto
glass fibre discs (Whatman GF/C), and lysed and washed
exhaustively with water prior to liquid scintillation counting.
Survivals were compared on the basis of D37, using Spearman
Rank correlation analysis.
Intracellular VP16-213 concentration
Intracellular accumulation of [3H]VP16-213 was studied using
the modified method of Hamza et al. (1987) with fewer cells
per replicate (I05cells/ml/replicate) and substituting VP16-
213 (1OItM) (900 mCimmol-'; Moravek Biochemicals, Brea,
USA) for VM-26, as radiolabelled VM-26 was unavailable.
Initially, cellular uptake was measured at time points ranging
from 5 to 120min at an extracellular [3H]VP16-213 concen-
tration of 10tM. The time-course of uptake was followed in
three medulloblastoma early passage cultures (MD 11, 12
and 14). Cellular uptake of [3H]VP16-213 at 120min was
used to compare differences between nine medulloblastoma
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Detection ofprotein-linked DNA strand breaks
The SDS-K+ precipitation method used was a modification
of that developed by Trask et al. (1984) and used to detect
drug damage by Rowe et al. (1986). All early passage cul-
tures used were harvested in log-phase growth. Cells were
labelled overnight with 0.8 iLM ml-I of 3H-thymidine (specific
activity 41 Ci mmol-') and cells (2 x 104 cells/vial) rested for
1 h at 37°C in a gassed (5% 02, 5% C02, 90% N2), humidi-
fied incubator. Drug was then added and cells incubated for
the required period. At different time points, the suspension
was diluted with 5 volumes Dulbecco's medium and spun at
150 x g for 10 min. Liquid scintillation counting was per-
formed following transfer of the pellet resuspended in 200
of water at 65°C into scintillation tubes containing 3.5 ml of
Instagel (Packard, Ill., USA). Additionally, cross-link repair
was determined by further incubation in drug free media.
Preparation ofnuclear lysate
Nuclear lysates were prepared according to the method of
Miller et al. (1981) but as limited numbers of cells were
available the method was scaled down 100-fold. Between 106
and 107 cells were used to make the lysates which were stored
at -20'C following dialysis against 30 mM potassium phos-
phate pH 7.0, 50% glycerol, 0.5 mM dithiothreitol and
0.1 mM EDTA.
Topoisomerase II activity
Topoisomerase II activity ofnuclear lysate from medulloblas-
toma early passage cultures was assessed using the P4 DNA
unknotting assay (Liu & Davis, 1981). Incubation was per-
formed for 1 h. The protein content of nuclear lysates was
measured by the Coomassie blue method of Bradford (1976).
Topoisomerase II expression
The topoisomerase II content was assessed by immunoblot-
ting ofcell extracts using anti-topoisomerase II antisera (Hal-
ligan et al., 1985). The topoisomerase II antibody was kindly
donated by Dr L.F. Liu (Johns Hopkins University, School
of Medicine, Baltimore, USA). Murine erythroleukaemia
cells (MELC), clone 745 of C. Friend, also donated by Dr
L.F. Liu, were used as controls.
Results
In vitro growth
All tumours plated in agar formed colonies (40 cells or more)
after 2 to 4 weeks culture. The cloning efficiency in agar, of
the four primary cultures tested, was very low (MD 4,
0.010 ± 0.001; MD 5, 0.0011 ± 0.0005; MD 7, 0.0023 ±
0.0009; MD 9, 0.0004 ± 0.0003; MD 10, 0.0015 ± 0.0002;
mean ± standard deviation). Most of the specimens provided
were not of sufficient size for plating in agar and therefore
primary cultures from these tumours were established in
liquid culture on plastic. Fourteen of 16 samples, including a
primary tumour and spinal metastasis, were established in
liquid culture.
Characterisation ofearly passage cultures
All early passage cultures were positive for the following
antibodies: UJ127.11 which recognises antigens on normal
ectodermal tissue, neuronal tumours and schwannomas;
UJ13A and A2B5 which recognise normal and neoplastic
neuroectodermal tissue; and UJ181.4 which recognises an
oncofoetal antigen expressed by foetal brain and neuroblastic
tumours. Staining for NSE was negative in all early passage
cultures. Karyotyping was successfully performed in eight out
of ten early passage cultures of which four were abnormal
(Table III). Of the four specimens submitted for flow cyto-
metry, two were aneuploid (Table III).
Table HI Cytogenetic and DNA flow-cytometric analysis of medul-
loblastoma early passage cultures
Cell
culture
MD 3
MD 4
MD 5
MD 6
MD 7
MD 9
MD 10
MD 11
MD 12
MD 13
MD 14
MD 15
MD 17
Karyotype
No metaphases
48,XY, + 8, + 21,del(4)(pl4)
46,XY, - 10, - 10,12p + ,t(3;14)(q21;q24),
+ 2mar
No metaphases
NA
46,XX
46,Y, - X,der(X)t(X;1) (p23.3;q21)
NA
48,XY, + Y,- 13,der(I)t(1;?)(p36.3;?),
der(11)t(1 1;?)(q23.1;?), del(17)(p11.2),
der(6)t(6;8)(pl 1.2;q22), + mar
46,XY
NA
46,XY
46,XY
DNAploidya
NA
NA
NA
NA
Aneuploid
NA
NA
Diploid
Diploid
NA
Aneuploid
NA
NA
aEarly passage cells with a DNA histogram indistinguishable from
normal HeLacellswereclassified asdiploid,however, inthecaseofMD
12,karyotypicanalysis indicatedadditionalchromosomeswerepresent.
NA not available.
Proliferative activity ofearlypassage cultures
Although the experiments were performed at the earliest
possible passages, the variation in control 3H-Thymidine
incorporation between experiments was still quite high,
decreasing as the cultures became older. Despite this varia-
tion, a reliable estimate ofdrug sensitivity was obtained. The
standard error of the mean of survival at a given drug
concentration obtained for three to ten experiments was
usually less than 10%. The average control values for incor-
porated d.p.m. are given in Figure 1. This average was taken
from all cytotoxicity experiments (approximately 30 to 100
independent experiments per culture, 12 control wells per
experiment).
Sensitivity tophase-specific agents
All three phase-specific agents in the '8 in 1' protocol (Pen-
dergrass et al., 1987) were tested i.c. AraC, HU and Vcr, and
the calculated D37 values are given in Table I. There was a
general trend for faster growing cells to be more sensitive to
the phase-specific agents. However, Spearman rank correla-
tion analysis was performed for each set of data and no
significant association was found between drug sensitivity
and d.p.m. in control cultures of the same experiments,
indicating that factors other than proliferative status also
influenced sensitivity to these agents.
There was a heterogeneous response to the phase-specific
agents, with the highest D37 being 40 times (Vcr), 43 times
100,000r
3 4 5 6 7 9 10 *eduflblastoma ulture
Figure 1 DPM incorporated into control cultures. The average
d.p.m. incorporated into each control well are given above. This
average was taken from all cytotoxicity experiments reported in
this paper, this being approximately 30 to 100 independent
experiments per culture. In each experiment at least six control
wells were used.1054 F.H. TOMLINSON et al.
(AraC) or 88 times (HU) higher than the lowest measured.
The fastest growing early passage culture, MD 12, was by far
the most sensitive to all three agents, but no culture was
consistently more resistant than others. Spearman rank cor-
relation analysis revealed no significant cross-sensitivity
between any combination of these agents. This again indi-
cates that factors other than those affecting cell growth deter-
mined in vitro sensitivity.
Only one tumour was considered sensitive to clinically
achievable levels of AraC and none to either HU or Vcr
(Table I). A very high concentration of HU was required to
kill cells when compared with plasma drug levels.
Sensitivity to epipodophyllotoxins
Similar experiments to those described above were carried
out using the epipodophyllotoxins VM-26 and VP16-213,
nonintercalative topoisomerase II poisons (Liu, 1989). The
response was heterogenous (Table I); the range of response
to VM-26 being greater than that for any other drug tested.
The in vitro response was not related to d.p.m. in control
cultures, but sensitivity to VM-26 was highly, significantly
correlated with response to VP16-213 (r = 0.852, P<0.002,
n = 13) (Table IV).
Twelve of 13 (92%) tumours were considered sensitive to
clinically achievable levels of VM-26 as were seven out of 13
(54%) to VP16-213 (Table I). This difference in responsive-
ness was due to two factors; on a molar basis, VM-26 was
far more cytotoxic than VP16-213, and the plasma pharma-
cokinetics reported for VP16-213 are worse than for VM-26,
because lower doses of VP16-213 must be administered and
for the same dose the C x T and the peak plasma concentra-
tion are lower (Table I). Most medulloblastoma cells were
very sensitive to VM-26. Ten of the sensitive early passage
cultures responded at levels which were less than 1/10 of that
achievable in patients and for one culture (MD 12) this figure
was 1/600. In this regard, VM-26 was the best agent tested in
this study.
Three early passage cultures however, were markedly more
resistant to VM-26 than average. The D37 values for these
cultures were 15.17IAM for MD5; 49.30 ,sm; for MD 7 and
11.60JM for MD 11. These cells were approximately 400-
1600 times as resistant as the most sensitive culture (MD 12,
D37 0.03 JAM) and 20 to 80 times more resistant than average
for the remaining cultures (D37 0.62JAM ± 0.35JAM s.d). The
same three early passage cultures were also resistant to VP16-
213. The difference between sensitive and resistant cultures
was not as marked as for VM-26, for D37 for the VP16-213
resistant cultures being around 300 times that of MD 12 and
13 times the average for the other nine early passage cultures.
Sensitivity to alkylating and cross-linking agents
Medulloblastoma early passage cultures were also tested for
sensitivity to alkylating and cross-linking agents i.e. BCNU,
Mfs, CDDP and AZQ (Table II). A spectrum of responses
Table IV Spearman rank correlation analysis of in vitro response
data
Variables ra P No.b
VM-26 & VP16-213 0.852 <0.002 13
VP16-213 & ASTA 0.902 <0.002 10
m-AMSA & VM-26 0.888 <0.002 12
m-AMSA & VP16-213 0.839 <0.002 12
m-AMSA & ASTA 0.685 <0.05 10
AZQ & control d.p.m. 0.982 <0.05 8
The data given in Tables I and II were analysed for cross-sensitivity
relationships between different agents. All possible combinations were
tested, and in addition the relationship between response to a drug and
the d.p.m. counted in control, untreated plates (ie. an indication ofthe
proliferative status of the cells) was also tested. ar, the probability of
there being a positive relationship between sensitivity to two different
agents, or between an agent and theproliferative status ofcontrol cells.
bNumber of early passage cultures tested.
was observed but the differences between the most sensitive
and most resistant cultures (D37 resistant cultures/D37 sen-
sitive culture) were less for this group of agents than for the
phase-specific agents. These ratios were five for BCNU, 23
for Mfs, 9 for CDDP and 16 for AZQ.
Early passage cultures resistant to the epipodophyllotoxins
(MD 5, MD 6, MD 7 and MD 11) were generally more
resistant than average to alkylating agents as well. MD 6
however appeared to be relatively sensitive to AZQ. Again,
MD 12 was the most sensitive to all these agents, but as
mentioned above, the differences between cultures were not
as great for this class of agents.
None of the tumours were sensitive to CDDP or AZQ but
seven of 12 were sensitive to BCNU and nine out of ten were
sensitive to Mfs (Table II). In all cases, the level of in vitro
drug exposure had to be of the same order of magnitude as
the maximum clinically achievable level to reduce survival to
37% of control, untreated cells. In other words, none of the
tumours tested were very sensitive to any agent from this
group.
Sensitivity to amsacrine (m-AMSA)
Sensitivity to a DNA intercalating topoisomerase II poison
(M-AMSA) (Liu, 1989) was tested (Figure 2). The range of
responses to this agent was large, the highest D37 calculated
being 399 times the lowest. MD 5 and MD7 were very
resistant to this agent, whilst MD 11 was only marginally
more resistant than average. Rank correlation analysis re-
vealed significant relationships between sensitivity to this
agent and epidodophyllotoxins, and also with Mfs (Table
IV).
Patterns ofcross-resistance and collateral sensitivity
As stated previously, the data in Tables I and II was analys-
ed for cross-resistance and collateral sensitivity relationships
by the Spearman rank correlation test (Table IV). Cross
resistance between VM-26 and VP16-213 was confirmed.
There was also a significant relationship between resistance
to these agents and to the other topoisomerase II poison
tested, m-AMSA.
There was no apparent relationship between sensitivity to
either VM-26, VP16-213 or m-AMSA and Vcr suggesting
that the phenomenon of 'pleiotropic drug resistance' may not
be responsible for the patterns of cross-resistance seen. Dose-
response experiments with VM-26 were also performed in the
presence of agents known to reverse this type of resistance:
verapamil (1OJM) (Yalowich & Ross, 1985) and cyclosporin
A (7 and 131igml-') (Slater et al., 1986). Neither of these
agents significantly altered sensitivity to VM-26 in any of the
early passage cultures tested; all cultures were tested except
for MD 10 and MD 17. A surprising finding was the associa-
tion between Mfs sensitivity and response to either VP16-213
or m-AMSA. The relationship with VM-26 was not signi-
ficant. The only dgent for which sensitivity was significantly
linked with the amount of 3H-thymidine incorporation in
control cells was AZQ. There was no significant difference
between results obtained from MD 6, the primary tumour
and MD 6M, a metastasis obtained from the same patient.
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Figure 2 Sensitivity ofmedulloblastoma to m-AMSA. aD37values
were calculated as outlined for Table I.
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Intracellular accumulation of VP16-213
Cellular uptake in medulloblastoma early passage cultures
measured at time points ranging from 5 to 120min demon-
strated that steady-state was achieved in all cultures by
60 min (Figure 3). Cellular uptake at 120 min in nine medul-
loblastoma cultures ranged from 4.88 to 20.26 pmol 10'
cells (Table V). The most resistant cultures fell in the
middle of this range (MD 5, 9.04; MD 7, 15.69; MD 11,
10.30 pmoles 10- cells), whilst the hypersensitive culture,
MD 12, had one of the lowest values. Estimation of cell
diameters allowed calculation ofthe cellular volume and thus
the intracellular drug concentration. Cell diameters ranged
from 17.8 to 19.9ym. The standard deviation ranged from
5% to 8% of the mean, indicating no significant difference
between cell diameters of different early passage cultures. It
was therefore calculated that all of these cultures were cap-
able of concentrating the drug. When the steady-state drug
concentration was compared with cellular drug sensitivity, no
correlation was found.
Protein-linked DNA strandbreak activity
Results were expressed as the ratio of the d.p.m. precipitated
in the presence ofdrug over d.p.m. precipitated without drug
(control). The fact that some precipitable counts were
measured in the absence of drug is an indication of the basal
level of topoisomerase II activity present. A range of VM-26
concentrations from 1 lAM to 1000tM were used initially
(Figure 4) and tested in six early passage cultures. Protein-
linked DNA strand breaks were found to occur at all concen-
trations tested. Maximum protein-linked DNA strand break
activity occurred at 300lM VM-26 except in one of the cul-
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Figure 3 Intracellular accumulation of VP16-213. Cellular
uptake of three medulloblastoma (MD) early passage cultures
measured at time points ranging from 5 to 120 min at an extra-
cellular [3H]VP16-213 concentration of 1OgM. Three experiments
testing each in duplicate were performed each culture. The mean
value±s.e.m. was calculated for each time point.
Table V Cellular uptake of[3H]VP16-213 in medullobastoma cells
Uptake Cell Cell Intracellular
(moles10' diameter volume 3H VP16-213
Culture cells x 10-12) (IxM) (1 X 10-12) (gLM)
MD 4 5.82±0.35 18.90 3.54 16.44±0.99
MD 5 9.04±2.10 18.60 3.37 26.82±6.23
MD 7 15.69±0.29 19.90 4.13 37.99±0.70
MD 11 10.30±2.71 17.80 2.95 34.92±9.19
MD 12 6.24± 1.16 17.90 3.00 20.80± 3.87
MD 13 20.26± 1.53 18.50 3.32 61.02±4.61
MD 14 5.60±0.76 18.20 3.16 17.72±2.40
MD 15 4.88±0.41 18.10 3.10 15.74±1.32
MD 17 14.46±2.31 18.40 3.26 44.36±7.09
Uptake was measured after a 2 h incubation with [3H]VP16-213 at
37°C. Duplicate determinations were performed for each experiment.
Mean uptake was calculated from the results from three experiments
expressed as + SEM.
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Figure 4 Protein-linked DNA strand break activity following the
1 h incubation with 1 jAM to 1I00JM VM-26. The mean±s.e.m.
were calculated for each time point for 3-8 experiments. Within
each experiment duplicate or triplicate determinations were per-
formed.
tures tested (MD 6), where maximum breaks occurred at
70itM. Above these concentrations, the number of protein-
linked DNA strand breaks decreased in spite of the higher
drug concentration.
Protein-linked DNA strand breaks were compared in all
available medulloblastoma early passage cultures following a
1 h incubation with 1OiM and 30 JAM VM-26. The latter
concentration was chosen since this was likely to result in
maximum DNA damage due to protein-linked DNA strand
breaks, is a clinically achievable concentration and is highly
cytotoxic in the 3H-thymidine assay. At the lower concentra-
tion of 10JM VM-26, the number of protein-linked DNA
strand breaks was elevated by a factor of approximately ten
times control. At 30iJM VM-26, the number ofprotein-linked
DNA strand breaks was elevated by a factor of around 20
times control. Some cultures exhibited less protein-linked
DNA strand break activity. MD 5, in particular, was resis-
tant to this form of drug-induced damage. No overall cor-
relation between epipodophyllotoxin sensitivity and induction
of protein-linked DNA strand breaks was apparent.
In medulloblastoma early passage cultures, VM-26 was
much more cytotoxic to cells on an equimolar basis than
VP16-213 (Table I). Experiments were performed to compare
the number of protein-linked DNA strand breaks produced
by VP16-213 and VM-26 in four medulloblastoma cultures.
Two of the four medulloblastoma early passage culture (MD
7, MD 11) were resistant to epipodophyllotoxins. The
number of protein-linked DNA strand breaks produced by
VM-26 was approximately 1.8 times greater than that pro-
duced by VP16-213.
Protein-linked DNA strandbreak time-course
Production of protein-linked DNA strand breaks by con-
tinuous exposure to VM-26 (1OJM and 30 JM), was measur-
ed in medulloblastoma early passage cultures for time points
10 min to 24 h (Figure 5). Generally, maximum protein-
linked DNA strand break frequency occurred at 1 h for both
drug concentrations. The time-course ofinduction ofprotein-
linked DNA strand breaks at 30JAM VM-26 in the VM-26
resistant cultures MD 7 and MD 11 was no different from
that of the sensitive lines MD 12, MD 14. In the VM-26
resistant culture MD 5, however, the frequency of protein-
linked DNA strand breaks did not vary with exposure dura-
tion. In spite of the continuous presence of VM-26, at time
points after 1 h, d.p.m. precipitated by SDS-K+ approached
control values.
After long term exposure to VM-26 (24 h) the frequency of
protein-linked DNA strand breaks at 10JAM and 30gM con-
centrations was not significantly different from control values
for early passage cultures other than MD 7. In this culture,
the frequency of protein-linked DNA strand breaks was 5.1
and 8.4 times control at 10JM and 30JLM respectively.
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Figure 5 Protein-linked DNA strand break activity produced over 24 h following incubation with a, 10jiM and b, 30juM VM-26.
The mean±s.e.m. were calculated for each time point for 3-8 experiments. Within each experiment duplicate or triplicate
determinations were performed.
mAMSA-inducedprotein-linked DNA strand breaks
Protein-linked DNA strand break activity was examined fol-
lowing exposure to m-AMSA (3 jig ml-I for 1 h and 24 h).
This concentration was chosen because it was a clinically
achievable level and resulted in significant cytotoxicity (being
of the order of the D37 for the medulloblastoma group). At
this concentration m-AMSA was readily soluble in RPMI
1640 10% FCS. At 1 h, significant protein-linked DNA
strand break activity was observed which was roughly equiv-
alent to that produced by 10OiM VM-26. Again, few links
were observed in the MD 5 early passage culture. After 24 h,
protein-linked DNA strand breaks were still apparent but
were lower than at 1 h.
Time course ofprotein-linked DNA strand break repair
Repair of protein-linked DNA strand breaks was investigated
in medulloblastoma early passage cultures (MD 7, 11, 12, 14,
15 and 17) after incubation with 30 jiM VM-26 for 1 h. After
washing, SDS-KCI precipitable d.p.m. were measured at
time-points ranging from 15 min to 24 h. The time-course of
repair of protein-linked DNA strand breaks was rapid and
similar for all cultures. Values approached control within 1 h
after removal of drug. In the VM-26 resistant culture MD 7,
values fell below control at 3 h. At 24 h values for all cul-
tures approximated control.
Topoisomerase II activity
Topoisomerase II activity in nuclear lysates from MD 5, 7,
12 and 14 cells was assayed using a P4 unknotting assay.
Extracts from MD 12 had the greatest amount of activity,
detectable with as little as 0.1 jig nuclear protein. Activity in
the other early passage cultures was much lower than MD 12
with detectable activity at 1 jig protein for MD 11 and 3 jig
for both MD 7 and MD 14. There was no detectable activity
in nuclear lysates from MD 5 cells.
Topoisomerase II expression
In three medulloblastoma early passage cultures, MD 7, MD
12, MD 14, a band of similar molecular weight to topoiso-
merase II (170 kDa) previously characterised in mouse friend
leukaemia cells (Bodley et al., 1987; personal communication
L.F. Liu, 1990), was identified. Consistent with the results of
the activity assay, the amount of enzyme was high in MD 12
cells and much lower in the other two cultures, with more
immunoreactive protein in MD 7 than MD 14. Insufficient
cells were available to enable enzyme expression in MD 5
and MD 11. Two bands of high molecular weight greater
than 180 kDa were recognised in the MD 7 cells but not the
other lines. A number of bands of lower molecular weight
were seen in all early passage cultures and presumably repre-
sent fragmented protein.
Discussion
The benefits of surgery and radiotherapy for treatment of
malignant disease are generally considered to be approaching
the maximal attainable limits. Further improvement in
disease free survival may be achieved by chemotherapy but
there is considerable heterogeneity of response to different
agents; both between patients and between tumour types.
The present study concentrated on medulloblastoma; a
tumour with a poor prognosis but where chemotherapy has
been shown to be advantageous for some patients (Evans et
al., 1990; Tait et al., 1990; Packer et al., 1991; Bloom, 1986).
We have examined the in vitro sensitivity of early passaged
cultures from 13 medulloblastoma patients to a number of
drugs. Since the cultures have not been extensively passage,
the possibility of selection from an originally heterogenous
sample of tumour cells is therefore diminished. The results
should give an indication of the degree of heterogeneity of
response between different tumours.
The clinical criteria for selection of tumour samples for use
in this study were based on: (a) demographic characteristics
and clinical presentation; (b) the radiologic appearance; (c)
the histologic appearance. The identity of the cultured cells
was determined on morphological (Rubinstein & Herman,
1986; Gerosa et al., 1987) immunohistochemical, cytogenetic
and DNA flow cgtometric analysis. The immunohistochem-
ical profile was determined using a panel of murine mono-
clonal antibodies (UJ13A, UJI81.4, UJ127.11 and A2B5).
These antibodies have been successfully used for the charac-
terisation ofsurgical material and established cell lines (Kem-
shead & Coakham, 1983; Bourne et al., 1986; He et al., 1989;
Coakham & Bourne, 1989).
As with surgical specimens of gliomas (Rosenbloom et al.,
1983), medulloblastoma primary cultures exhibited poor
cloning efficiencies in semisolid media in contrast to the high
cloning efficiency seen in an established medulloblastoma cell
line Daoy (Jacobsen et al., 1985). However, medulloblastoma
is unlike gliomas in that clonal growth on plastic is hard to
assess due to cell mobility and poor growth at low cell
density. In this study, we used an end-point of cellular 3H-
thymidine uptake 5-7 days after drug exposure as an indi-
cator of drug toxicity. This has been found to correlate with
clonal growth in agar (Parsons & Brown, 1979).
The cut-off used for sensitivity in the present study was
that found by others to predict clinical response (approxi-
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mately 100% correct for resistance, 70% for sensitivity)
(Salmon et al., 1980; Moon et al., 1981; Rosenbloom et al.,
1983; Bogdahn, 1983; Kornblith et al., 1981; Kimmel et al.,
1987); except that the D37 rather than D4, was used. The
parameter used as a measure of maximum possible in vivo
drug exposure (in the clinical situation) was the C x T (drug
concentration x duration of exposure). This is considered to
be a more relevant pharmacokinetic parameter than concen-
tration or duration of exposure alone in determining re-
sponse to drugs (Mellett, 1974; Alberts et al., 1980). The
C x T of in vitro exposure was calculated to parallel reported
in vivo C x T values. Exposures of 4 h duration were used for
drugs which are not phase-specific. A 24 h incubation was
used for drugs which demonstrate phase-specificity and have
relatively long plasma half-lives. This approach has been
successful in this laboratory in studies of acute myeloid
leukaemia (Lihou & Smith, 1985).
We have thus found that two of the agents conventionally
used for treatment of medulloblastoma are active against
most of our early passage cultures in vitro i.e. Mfs, the
cyclophosphamide analogue and BCNU. On the other hand,
some agents did not exhibit activity, i.e. cis-platin, hydroxy-
urea, vincristine and cytosine arabinoside. The relatively new
agent, diaziquone (AZQ) was also not effective. The most
promising results were those for the epipodophyllotoxin VM-
26. The epipodophyllotoxins are generally believed to be of
equivalent clinical value, with no established evidence of
superiority of one agent over another (Issell et al., 1982). Our
study demonstrated in vitro cross-resistance between these
agents, but we found that in all cases VM-26 was more
cytotoxic to medulloblastoma than VP16-213. Issell et al.
(1982) also found a significant difference between activity of
these two compounds against a sample of brain tumours. In
the present study, D37 values for VP16-213 were higher in all
cases than for VM-26 (1.3 to 32.8 times VM-26 D37). When
in vivo pharmacokinetics are considered, this difference in D37
meant that 12/13 medulloblastomas were predicted to be
clinically sensitive to VM-26 but only 7/13 to VP16-213.
When cytotoxic concentrations were compared with clinically
achievable drug concentrations, VM-26 was the best of all
the agents tested with the D37 for most early passage cultures
being around one tenth of the plasma C x T.
Friedman et al. (1988) found the medulloblastoma lines
D283 Med and Daoy were sensitive to active cyclophos-
phamide analogues. The ID90's of D283 Med and Daoy to
4-hydroperoxycyclophosphamide (22.47 ylM and 29.90jtM respectively for a 1 h incubation) are much lower than D37
values measured for our early passage medulloblastoma cells,
with the exception of MD 12. This is not unexpected as it is
common for established cell lines to be more sensitive to
cytotoxic drugs than early passage tumour cells (Weisenthal,
1981; Tveit et al., 1981).
Additionally, Friedman et al. (1988) found BCNU to be
ineffective in vivo, which the authors suggested was due to the
presence in the xenografts of high levels of 06-alkylguanine-
DNA alkyltransferase (Schold et al., 1989). Sensitivity to
BCNU was demonstrated in 7/12 of the early passage cul-
tures tested in this study. Our results are similar to those
obtained by Rosenbloom et al. (1983) and Kornblith et al.
(1981). Medulloblastomas as a group are more sensitive to
BCNU than the gliomas but exhibit the same type of dose-
response curves to BCNU. These curves are characterised by
a small response at low doses of drug, with a greater degree
of sensitivity exhibited above a limiting concentration. This
point of inflection on the dose-response curve unfortunately often occurs above C xTm.. Reports of the possible benefits
obtained by intracarotid administration of this short-lived
compound (Feun et al., 1985; Watne et al., 1990) are consis-
tent with this high dose requirement.
Because of the identification of the epipodophyllotoxins as
agents active against medulloblastoma and the availability of
three early passage cultures with marked clinically acquired resistance to these agents, the biochemical basis ofsensitivity/ resistance was investigated.
A number of authors have characterised the basis ofepipo-
dophyllotoxin resistance in non-medulloblastoma cell lines
and found it to be due to alterations in drug transport and
associated with 'pleiotropic drug resistance' (Yalowich &
Ross, 1985). Although the medulloblastoma cells exhibited
cross-resistance between epipodophyllotoxins, m-AMSA and
Mfs, there was no cross-resistance with Vcr, a drug usually
associated with multiple drug resistance. Further experiments
showed that the resistance could not be reversed by verap-
amil, nor was there any meaningful difference between
steady-state intracellular drug concentrations in the different
early passage cultures. Thus the phenomenon of 'pleiotropic
drug resistance,' or a more specific drug transport mechan-
ism, was excluded as the mechanism ofresistance in our early
passage cultures.
Cross-resistance between VM-26 and m-AMSA suggested
that modifications in amount or activity of topoisomerase II
may be responsible for the difference in drug sensitivity. Both
epipodophyllotoxins and m-AMSA, together with anthra-
cyclics, ellipticine and actinomycin D have been shown to
inhibit topoisomerase II activity and induce the formation of
enzyme-linked DNA strand breaks (Zwelling, 1985). The
level ofprotein-linked DNA breaks is most closely associated
with cytotoxicity (Rowe et al., 1986), whilst inhibition of
enzyme actually appears to be less important. The amount of
protein-linked DNA strand breaks found and the subsequent
cytotoxicity appear to be related to the amount of enzyme
present; cells with a higher enzyme content as measured by
either immune serum or activity assays are more sensitive to
the topoisomerase II active drugs (Pommier et al., 1986; Per
et al., 1987). This, however, is not always the case. It has
been proposed that an alteration of activity (Glisson et al.,
1986) or differential activity of two different forms of the
enzyme explains decreased protein-linked DNA strand breaks
in resistant cells (Drake et al., 1987). More recently, a second
form oftopoisomerase II, the p180 form, or topoisomerase II
P has been characterised and this may explain non-MDR
mediated resistance to topoisomerase II a inhibitors (Drake
et al., 1989). We have identified heavier forms of topo-
isomerase II in MD 7. However, the topoisomerase II P form
described is not identified by the monoclonal antibody used
in this study. This suggests that the heavier form identified in
MD 7 may be transformed topoisomerase II a (Dr L.F. Liu,
personal communication). Further characterisation of these
forms is beyond the scope of this study.
The level of protein-linked DNA strand breaks induced by
epipodophyllotoxins in medulloblastoma early passage cul-
tures was not indicative of cytotoxicity. The profile of resis-
tant early passage culture MD 5 was typical of reported
resistant non-medulloblastoma cell lines: very low cross-
linking, undetectable enzyme activity. It was also the slowest
growing culture. The other epipodophyllotoxin resistant early
passage cultures (MD 7, MD 11) however, did not differ
from sensitive cultures or the hypersensitive culture (MD 12)
in protein-linked DNA strand break activity or enzyme activ-
ity. Drug resistance could not be explained by differences in
repair of cross-linking.
Protein-linked DNA strand breaks in the presence of VM-
26 increased up to about 1 h, and then decreased. At 4 h
there were fewer K+-SDS precipitable counts than at earlier
time points although VM-26 was still present and levels in
controls did not decrease. It seems unlikely that this is due to
repair in the presence of drug. It may be an indication that
programmed cell death has been initiated and the relevant
endonuclease has begun the process of DNA fragmentation,
documented as an early stage of this phenomenon (Wyllie,
1987). After 24 h continuous exposure to VM-26 the precipi-
table counts approach control values indicating either that
the cells are refractory to further damage and complete repair
of lesions has been carried out, or extensive degradation of
the DNA attached to protein has occurred. This will be
further investigated by gel electrophoresis of DNA from
these 24 h treated cells.
In conclusion, our study demonstrates a heterogeneity of
response of a number ofearly passage medulloblastoma cul-
tures to the chemotherapeutic agents tested. The epipodo-1058 F.H. TOMLINSON et al.
phyllotoxins, in particular VM-26, were the best class of
chemotherapy agents tested, while some drugs in clinical use,
were found to be ineffective. In vitro chemosensitivity testing
of early passage medulloblastoma cultures, more represen-
tative of the tumour than established cell lines, provides a
method for the selection of agents for use in chemotherapy
regimens. With the current trend for pre-irradiation chemo-
therapy and use of chemotherapy alone in babies and very
young children, this should be a valuable method, but the
time interval necessary to test a battery of chemotherapeutic
agents and the limited amount ofmaterial often available for
multiple drug testing detract from its clinical applicability.
Manipulation of early passage cultures, with cell growth
factors, providing that this does not induce changes in geno-
type, may provide a rapid in vitro method which would allow
selection of a patient specific chemotherapy protocol.
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